JNJ vs DGX
By Alex · Tickerpine
Johnson & Johnson vs Quest Diagnostics Incorporated, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | DGX |
|---|---|---|
| Price | $273.14 | $244.51 |
| Market cap | $658.24B | $26.99B |
| P/E ratio | 31.7 | 26.0 |
| ROE | 25.74% | 14.60% |
| Profit margin | 21.48% | 9.19% |
| Revenue growth | 6.60% | 10.20% |
| Dividend yield | 1.96% | 1.41% |
| Beta | 0.23 | 0.55 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs DGX in plain English
- JNJ is the bigger company — about 24.4× the market cap of DGX.
- DGX is cheaper on earnings (P/E 26.0 vs 31.7).
- JNJ earns a higher return on equity (26% vs 15%).
- DGX is growing revenue faster (10% vs 7%).
- JNJ has the higher dividend yield (1.96% vs 1.41%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
DGX return calculator
See what $1,000 in Quest Diagnostics Incorporated would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.